Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Episode 100: Colorectal Cancer Series, Pt. 2 - Adjuvant Therapy in Stage III Colon Cancer

Episode 100: Colorectal Cancer Series, Pt. 2 - Adjuvant Therapy in Stage III Colon Cancer

FromThe Fellow on Call: The Heme/Onc Podcast


Episode 100: Colorectal Cancer Series, Pt. 2 - Adjuvant Therapy in Stage III Colon Cancer

FromThe Fellow on Call: The Heme/Onc Podcast

ratings:
Length:
20 minutes
Released:
Apr 24, 2024
Format:
Podcast episode

Description

This week, we kick off our discussion of adjuvant systemic treatment in colon cancer, beginning with Stage III colon cancer. We will review the evidence basis for adjuvant therapy as well as the two main chemotherapy regimens including duration and side effects. Content: - Why do we need adjuvant therapy in stage III colon cancer? - What is FOLFOX? What is CAPOX? When do we use what?- What is the optimal duration of therapy? - What are the characteristics deemed high risk? - Can we discontinue oxaliplatin early? - What is the role of oxaliplatin in older patients? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast
Released:
Apr 24, 2024
Format:
Podcast episode

Titles in the series (100)

We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.